Eli Lilly 2008 Annual Report Download - page 84

Download and view the complete annual report

Please find page 84 of the 2008 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

PROXY STATEMENT
8282
Committees of the Board of Directors
Audit Committee
The duties of the audit committee are described in the “Audit Committee Report” found on pages 86–87.
Directors and Corporate Governance Committee
The duties of the directors and corporate governance committee are described on page 85.
Compensation Committee
The duties of the compensation committee are described on pages 88–89, and the “Compensation Committee
Report” is shown on page 99.
Public Policy and Compliance Committee
• oversees the processes by which the company conducts its business so that the company will do so in a manner
that complies with laws and regulations and refl ects the highest standards of integrity
• reviews and makes recommendations regarding policies, practices, and procedures of the company that relate to
public policy and social, political, and economic issues that may affect the company.
Finance Committee
• reviews and makes recommendations regarding capital structure and strategies, including dividends, stock
repurchases, capital expenditures, fi nancings and borrowings, and signifi cant business development projects.
Science and Technology Committee
• reviews and makes recommendations regarding the company’s strategic research goals and objectives
• reviews new developments, technologies, and trends in pharmaceutical research and development
• reviews scientifi c aspects of signifi cant business development projects.
Me mbership and Meetings of the Board and Its Committees
In 2008, each director attended more than 85 percent of the total number of meetings of the board and the
committees on which he or she serves. In addition, all board members are expected to attend the annual meeting
of shareholders, and all but one attended in 2008. Current committee membership and the number of meetings of
the board and each committee in 2008 are shown in the table below.
Name Board Audit Compensation
Directors and
Corporate
Governance Finance
Public
Policy and
Compliance
Science and
Technology
Mr. Alvarez 1 Member Member Member
Sir Winfried Bischoff Member Member Chair
Mr. Cook Member Chair Member
Mr. Eskew Member Member Member
Dr. Feldstein Member Member Member Chair
Mr. Fisher 2
Mr. Fyrwald Member Member Member
Dr. Gilman Member Member Chair
Ms. Horn Presiding Director Chair Member
Dr. Lechleiter Chair
Ms. Marram Member Member Chair
Mr. Oberhelman 3 Member Member Member
Dr. Prendergast Member Member Member
Ms. Seifert Member Member Member
Mr. Taurel 4
Number of 2008 Meetings9 996555
1 Mr. Alvarez’s term begins April 1, 2009.
2 Mr. Fisher retired from the board as of April 21, 2008.
3 Mr. Oberhelman joined the board as of December 1, 2008.
4 Mr. Taurel retired from the board as of December 31, 2008.